Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.
Individual Disclosures for the NCCN Pediatric Acute Lymphoblastic Leukemia Panel
MaH, SunH, SunX. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep 2014;4:4227.2457237810.1038/srep04227)| false
PulteD, GondosA, BrennerH. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood2009;113:1408–1411.
PulteD, GondosA, BrennerH. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113:1408–1411.1897437110.1182/blood-2008-06-164863)| false
PulteD, JansenL, GondosA, . Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One 2014;9:e85554.2447504410.1371/journal.pone.0085554)| false
PietersR, De LorenzoP, AncliffeP, et al.. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study. J Clin Oncol2019;37:2246–2256.
PietersR, De LorenzoP, AncliffeP, . Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study. J Clin Oncol 2019;37:2246–2256.3128340710.1200/JCO.19.00261)| false
KarimiM, CohanN, ZareifarS, . Initial presentation of childhood leukaemia with facial palsy: three case reports. BMJ Case Rep 2009;2009.10.1136/bcr.10.2008.104622162740)| false
Kraigher-KrainerE, LacknerH, SovinzP, et al.. Numb chin syndrome as initial manifestation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer2008;51:426–428.
Kraigher-KrainerE, LacknerH, SovinzP, . Numb chin syndrome as initial manifestation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;51:426–428.10.1002/pbc.21627)| false
SwerdlowSH, CampoE, HarrisNL, et al., editors. B-lymphoblastic leukaemia/lymphoma, not otherwise specified (NOS). In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France:IARC; 2017: 200.
SwerdlowSH, CampoE, HarrisNL, , editors. B-lymphoblastic leukaemia/lymphoma, not otherwise specified (NOS). In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France:IARC; 2017: 200.)| false
AminHM, YangY, ShenY, et al.. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia2005;19:1567–1572.
AminHM, YangY, ShenY, . Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 2005;19:1567–1572.10.1038/sj.leu.240387616049515)| false
WeinkauffR, EsteyEH, StarostikP, et al.. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol1999;111:733–740.
WeinkauffR, EsteyEH, StarostikP, . Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999;111:733–740.1036150710.1093/ajcp/111.6.733)| false
SwerdlowSH, CampoE, HarrisNL, et al., editors. T-lymphoblastic leukaemia/lymphoma. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.4th ed.Lyon, France:IARC;2017:209.
SwerdlowSH, CampoE, HarrisNL, , editors. T-lymphoblastic leukaemia/lymphoma. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.4th ed.Lyon, France:IARC;2017:209.)| false
SwerdlowSH, CampoE, HarrisNL, et al., editors. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed.Lyon, France:IARC; 2017:203.
SwerdlowSH, CampoE, HarrisNL, , editors. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed.Lyon, France:IARC; 2017:203.)| false
ArberDA, OraziA, HasserjianR, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood2016;127:2391–2405.
ArberDA, OraziA, HasserjianR, . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–2405.10.1182/blood-2016-03-64354427069254)| false
Den BoerML, van SlegtenhorstM, De MenezesRX, et al.. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol2009;10:125–134.
Den BoerML, van SlegtenhorstM, De MenezesRX, . A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125–134.10.1016/S1470-2045(08)70339-5)| false
HarrisonCJ, MoormanAV, SchwabC, et al.. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia2014;28:1015–1021.
HarrisonCJ, MoormanAV, SchwabC, . An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2014;28:1015–1021.10.1038/leu.2013.317)| false
MoormanAV, EnsorHM, RichardsSM, et al.. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol2010;11:429–438.
MoormanAV, EnsorHM, RichardsSM, . Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010;11:429–438.2040975210.1016/S1470-2045(10)70066-8)| false
MoormanAV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica2016;101:407–416.
MoormanAV. New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica 2016;101:407–416.2703323810.3324/haematol.2015.141101)| false
RaimondiSC, ZhouY, MathewS, et al.. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer2003;98:2715–2722.
RaimondiSC, ZhouY, MathewS, . Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003;98:2715–2722.10.1002/cncr.1184114669294)| false
MoormanAV, ChiltonL, WilkinsonJ, . A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010;115:206–214.10.1182/blood-2009-07-23212419897583)| false
SchultzKR, PullenDJ, SatherHN, et al.. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood2007;109:926–935.
SchultzKR, PullenDJ, SatherHN, . Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 2007;109:926–935.10.1182/blood-2006-01-02472917003380)| false
MühlbacherV, ZengerM, SchnittgerS, et al.. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer2014;53:524–536.
MühlbacherV, ZengerM, SchnittgerS, . Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer 2014;53:524–536.10.1002/gcc.2216324619868)| false
BehmFG, RaimondiSC, FrestedtJL, et al.. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood1996;87:2870–2877.
BehmFG, RaimondiSC, FrestedtJL, . Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996;87:2870–2877.863990610.1182/blood.V87.7.2870.bloodjournal8772870)| false
HildenJM, DinndorfPA, MeerbaumSO, et al.. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood2006;108:441–451.
HildenJM, DinndorfPA, MeerbaumSO, . Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006;108:441–451.10.1182/blood-2005-07-301116556894)| false
PietersR, SchrappeM, De LorenzoP, et al.. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet2007;370:240–250.
PietersR, SchrappeM, De LorenzoP, . A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240–250.10.1016/S0140-6736(07)61126-X)| false
PuiCH, GaynonPS, BoyettJM, et al.. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet2002;359:1909–1915.
PuiCH, GaynonPS, BoyettJM, . Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359:1909–1915.1205755410.1016/S0140-6736(02)08782-2)| false
FischerU, ForsterM, RinaldiA, et al.. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet2015;47:1020–1029.
InukaiT, HiroseK, InabaT, et al.. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia2007;21:288–296.
FeliceMS, GallegoMS, AlonsoCN, et al.. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols. Leuk Lymphoma2011;52:1215–1221.
FeliceMS, GallegoMS, AlonsoCN, . Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols. Leuk Lymphoma 2011;52:1215–1221.10.3109/10428194.2011.565436)| false
HeeremaNA, CarrollAJ, DevidasM, et al.. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol2013;31:3397–3402.
HeeremaNA, CarrollAJ, DevidasM, . Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group. J Clin Oncol 2013;31:3397–3402.10.1200/JCO.2013.49.130823940221)| false
MoormanAV, RobinsonH, SchwabC, et al.. Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol2013;31:3389–3396.
MoormanAV, RobinsonH, SchwabC, . Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials. J Clin Oncol 2013;31:3389–3396.2394022010.1200/JCO.2013.48.9377)| false
MoormanAV, RichardsSM, RobinsonHM, et al.. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood2007;109:2327–2330.
MoormanAV, RichardsSM, RobinsonHM, . Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007;109:2327–2330.10.1182/blood-2006-08-04043617095619)| false
AricòM, ValsecchiMG, CamittaB, et al.. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med2000;342:998–1006.
AricòM, ValsecchiMG, CamittaB, . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998–1006.10.1056/NEJM20000406342140210749961)| false
MullighanCG, MillerCB, RadtkeI, . BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110–114.10.1038/nature0686618408710)| false
MullighanCG, SuX, ZhangJ, . Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470–480.1912952010.1056/NEJMoa0808253)| false
BoerJM, van der VeerA, RizopoulosD, et al.. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia2016;30:32–38.
BoerJM, van der VeerA, RizopoulosD, . Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016;30:32–38.2620293110.1038/leu.2015.199)| false
ClappierE, AuclercMF, RapionJ, et al.. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia2014;28:70–77.
ClappierE, AuclercMF, RapionJ, . An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 2014;28:70–77.10.1038/leu.2013.27724064621)| false
ZaliovaM, ZimmermannovaO, DörgeP, et al.. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia2014;28:182–185.
ZaliovaM, ZimmermannovaO, DörgeP, . ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 2014;28:182–185.10.1038/leu.2013.28224072102)| false
BerntKM, HungerSP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol 2014;4:54.10.3389/fonc.2014.0005424724051)| false
RobertsKG, GuZ, Payne-TurnerD, et al.. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol2017;35:394–401.
RobertsKG, GuZ, Payne-TurnerD, . High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 2017;35:394–401.10.1200/JCO.2016.69.007327870571)| false
van der VeerA, WaandersE, PietersR, et al.. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood2013;122:2622–2629.
van der VeerA, WaandersE, PietersR, . Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122:2622–2629.10.1182/blood-2012-10-462358)| false
HarveyRC, MullighanCG, ChenIM, et al.. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood2010;115:5312–5321.
HarveyRC, MullighanCG, ChenIM, . Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010;115:5312–5321.10.1182/blood-2009-09-245944)| false
ReshmiSC, HarveyRC, RobertsKG, et al.. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood2017;129:3352–3361.
ReshmiSC, HarveyRC, RobertsKG, . Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group. Blood 2017;129:3352–3361.10.1182/blood-2016-12-75897928408464)| false
RobertsKG, YangYL, Payne-TurnerD, et al.. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Adv2017;1:1657–1671.
RobertsKG, YangYL, Payne-TurnerD, . Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. Blood Adv 2017;1:1657–1671.29296813)| false
Hernandez TejadaFN, Galvez SilvaJR, Zweidler-McKayPA. The challenge of targeting notch in hematologic malignancies. Front Pediatr 2014;2:54.10.3389/fped.2014.00054)| false
WengAP, FerrandoAA, LeeW, . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–271.10.1126/science.1102160)| false
AsnafiV, BuzynA, Le NoirS, et al.. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood2009;113:3918–3924.
AsnafiV, BuzynA, Le NoirS, . NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009;113:3918–3924.10.1182/blood-2008-10-184069)| false
ClappierE, ColletteS, GrardelN, et al.. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia2010;24:2023–2031.
ClappierE, ColletteS, GrardelN, . NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010;24:2023–2031.10.1038/leu.2010.20520861920)| false
TrinquandA, Tanguy-SchmidtA, Ben AbdelaliR, et al.. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol2013;31:4333–4342.
TrinquandA, Tanguy-SchmidtA, Ben AbdelaliR, . Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31:4333–4342.10.1200/JCO.2012.48.5292)| false
JenkinsonS, KirkwoodAA, GouldenN, et al.. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia2016;30:39–47.
JenkinsonS, KirkwoodAA, GouldenN, . Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia 2016;30:39–47.10.1038/leu.2015.20626220040)| false
ZuurbierL, HommingaI, CalvertV, et al.. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia2010;24:2014–2022.
ZuurbierL, HommingaI, CalvertV, . NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010;24:2014–2022.2086190910.1038/leu.2010.204)| false
RobertsKG, ReshmiSC, HarveyRC, et al.. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood2018;132:815–824.
RobertsKG, ReshmiSC, HarveyRC, . Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood 2018;132:815–824.2999722410.1182/blood-2018-04-841676)| false
HarveyRC, KangH, RobertsKG, et al.. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention. Blood2013;122:826.
HarveyRC, KangH, RobertsKG, . Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention. Blood 2013;122:826.)| false
InabaH, AzzatoEM, MullighanCG. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: The St. Jude Children’s Hospital approach. Front Pediatr2017;5:258.
InabaH, AzzatoEM, MullighanCG. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: The St. Jude Children’s Hospital approach. Front Pediatr 2017;5:258.2925570110.3389/fped.2017.00258)| false
HasleH, ClemmensenIH, MikkelsenM. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 2000;355:165–169.1067511410.1016/S0140-6736(99)05264-2)| false
SmithM, ArthurD, CamittaB, et al.. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol1996;14:18–24.
SmithM, ArthurD, CamittaB, . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18–24.855819510.1200/JCO.1996.14.1.18)| false
VroomanLM, BlonquistTM, HarrisMH, et al.. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv2018;2:1449–1458.
GadnerH, MaseraG, SchrappeM, et al.. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop (‘Ponte di legno meeting’) report: Vienna, Austria, April 27-28, 2005. Leukemia2006;20:9–17.
SutcliffeMJ, ShusterJJ, SatherHN, et al.. High concordance from independent studies by the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children’s Oncology Group (COG) initiative. Leukemia2005;19:734–740.
SutcliffeMJ, ShusterJJ, SatherHN, . High concordance from independent studies by the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children’s Oncology Group (COG) initiative. Leukemia 2005;19:734–740.15789069)| false
RomanaSP, MauchaufféM, Le ConiatM, . The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995;85:3662–3670.10.1182/blood.V85.12.3662.bloodjournal85123662)| false
PatrickK, WadeR, GouldenN, et al.. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol2014;166:421–424.
PatrickK, WadeR, GouldenN, . Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014;166:421–424.10.1111/bjh.12882)| false
WinterSS, DunsmoreKP, DevidasM, et al.. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol2018;36:2926–2934.
WinterSS, DunsmoreKP, DevidasM, . Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol 2018;36:2926–2934.10.1200/JCO.2018.77.7250)| false
PuiCH, PeiD, SandlundJT, et al.. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia2010;24:371–382.
SilvermanLB, DeclerckL, GelberRD, et al.. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia2000;14:2247–2256.
SilvermanLB, DeclerckL, GelberRD, . Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247–2256.1118791610.1038/sj.leu.2401980)| false
SilvermanLB, StevensonKE, O’BrienJE, et al.. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia2010;24:320–334.
SilvermanLB, StevensonKE, O’BrienJE, . Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010;24:320–334.10.1038/leu.2009.25320016537)| false
MörickeA, ZimmermannM, ReiterA, et al.. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia2010;24:265–284.
MörickeA, ZimmermannM, ReiterA, . Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265–284.10.1038/leu.2009.257)| false
SchrappeM, ReiterA, LudwigWD, et al.. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood2000;95:3310–3322.
KlukMJ, LindsleyRC, AsterJC, et al.. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. J Mol Diagn2016;18:507–515.
SeibelNL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology (Am Soc Hematol Educ Program)2008;2008:374–380.
SeibelNL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology (Am Soc Hematol Educ Program) 2008;2008:374–380.10.1182/asheducation-2008.1.374)| false
KampsWA, BökkerinkJP, Hakvoort-CammelFG, et al.. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia2002;16:1099–1111.
KampsWA, BökkerinkJP, Hakvoort-CammelFG, . BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099–1111.10.1038/sj.leu.240248912040440)| false
MörickeA, ReiterA, ZimmermannM, et al.. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood2008;111:4477–4489.
MörickeA, ReiterA, ZimmermannM, . Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–4489.10.1182/blood-2007-09-11292018285545)| false
SeibelNL, SteinherzPG, SatherHN, et al.. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood2008;111:2548–2555.
SeibelNL, SteinherzPG, SatherHN, . Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008;111:2548–2555.10.1182/blood-2007-02-07034218039957)| false
StockW, LaM, SanfordB, et al.. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood2008;112:1646–1654.
StockW, LaM, SanfordB, . What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646–1654.10.1182/blood-2008-01-130237)| false
LarsonRA, DodgeRK, BurnsCP, et al.. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood1995;85:2025–2037.
LarsonRA, DodgeRK, BurnsCP, . A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025–2037.10.1182/blood.V85.8.2025.bloodjournal8582025)| false
BostromBC, SenselMR, SatherHN, et al.. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood2003;101:3809–3817.
BostromBC, SenselMR, SatherHN, . Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2003;101:3809–3817.10.1182/blood-2002-08-245412531809)| false
MitchellCD, RichardsSM, KinseySE, et al.. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol2005;129:734–745.
MitchellCD, RichardsSM, KinseySE, . Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734–745.1595299910.1111/j.1365-2141.2005.05509.x)| false
PuiCH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology (Am Soc Hematol Educ Program)2006;2006:142–146.
PuiCH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology (Am Soc Hematol Educ Program) 2006;2006:142–146.10.1182/asheducation-2006.1.142)| false
MörickeA, ZimmermannM, ValsecchiMG, et al.. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood2016;127:2101–2112.
MörickeA, ZimmermannM, ValsecchiMG, . Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016;127:2101–2112.10.1182/blood-2015-09-67072926888258)| false
TeuffelO, KusterSP, HungerSP, et al.. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia2011;25:1232–1238.
TeuffelO, KusterSP, HungerSP, . Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25:1232–1238.10.1038/leu.2011.8421527934)| false
AvramisVI, SencerS, PericlouAP, et al.. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood2002;99:1986–1994.
AvramisVI, SencerS, PericlouAP, . A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002;99:1986–1994.10.1182/blood.V99.6.198611877270)| false
SilvermanLB, BlonquistTM, HuntSK, et al.. Randomized Study of pegaspargase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL Consortium Protocol 11-001. Blood2016;128:175–175.
SilvermanLB, BlonquistTM, HuntSK, . Randomized Study of pegaspargase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of DFCI ALL Consortium Protocol 11-001. Blood 2016;128:175–175.10.1182/blood.V128.22.175.175)| false
ChrzanowskaM, KoleckiP, Duczmal-CichockaB, et al.. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci1999;8:329–334.
ChrzanowskaM, KoleckiP, Duczmal-CichockaB, . Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci 1999;8:329–334.1042538310.1016/S0928-0987(99)00027-5)| false
HawwaAF, CollierPS, MillershipJS, et al.. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol2008;66:826–837.
HawwaAF, CollierPS, MillershipJS, . Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 2008;66:826–837.1882330610.1111/j.1365-2125.2008.03281.x)| false
Collie-DuguidES, PritchardSC, PowrieRH, et al.. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics1999;9:37–42.
Collie-DuguidES, PritchardSC, PowrieRH, . The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37–42.1020864110.1097/00008571-199902000-00006)| false
McLeodHL, LinJS, ScottEP, et al.. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther1994;55:15–20.
McLeodHL, LinJS, ScottEP, . Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15–20.829931210.1038/clpt.1994.4)| false
RellingMV, SchwabM, Whirl-CarrilloM, et al.. Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther2019;105:1095–1105.
BhatiaS, LandierW, ShangguanM, et al.. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol2012;30:2094–2101.
BhatiaS, LandierW, ShangguanM, . Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol 2012;30:2094–2101.10.1200/JCO.2011.38.992422564992)| false
RichardsS, PuiCH, GayonP. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer2013;60:185–195.
RichardsS, PuiCH, GayonP. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2013;60:185–195.10.1002/pbc.2422822693038)| false
BalduzziA, ValsecchiMG, UderzoC, et al.. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet2005;366:635–642.
BalduzziA, ValsecchiMG, UderzoC, . Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635–642.10.1016/S0140-6736(05)66998-X)| false
LeungW, CampanaD, YangJ, et al.. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood2011;118:223–230.
LeungW, CampanaD, YangJ, . High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118:223–230.10.1182/blood-2011-01-33307021613256)| false
EapenM, RubinsteinP, ZhangMJ, et al.. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet2007;369:1947–1954.
EapenM, RubinsteinP, ZhangMJ, . Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369:1947–1954.10.1016/S0140-6736(07)60915-517560447)| false
DreyerZE, DinndorfPA, CamittaB, et al.. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol2011;29:214–222.
DreyerZE, DinndorfPA, CamittaB, . Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children’s Oncology Group. J Clin Oncol 2011;29:214–222.2113527910.1200/JCO.2009.26.8938)| false
MannG, AttarbaschiA, SchrappeM, et al.. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood2010;116:2644–2650.
MannG, AttarbaschiA, SchrappeM, . Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010;116:2644–2650.10.1182/blood-2010-03-273532)| false
BiondiA, GandemerV, De LorenzoP, et al.. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol2018;5:e641–e652.
BiondiA, SchrappeM, De LorenzoP, et al.. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol2012;13:936–945.
BiondiA, SchrappeM, De LorenzoP, . Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012;13:936–945.10.1016/S1470-2045(12)70377-722898679)| false
SchultzKR, BowmanWP, AledoA, et al.. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol2009;27:5175–5181.
SchultzKR, BowmanWP, AledoA, . Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009;27:5175–5181.10.1200/JCO.2008.21.251419805687)| false
SchultzKR, CarrollA, HeeremaNA, et al.. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia2014;28:1467–1471.
SchultzKR, CarrollA, HeeremaNA, . Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia 2014;28:1467–1471.10.1038/leu.2014.3024441288)| false
SlaytonWB, SchultzKR, KairallaJA, et al.. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol2018;36:2306–2314.
SlaytonWB, SchultzKR, KairallaJA, . Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol 2018;36:2306–2314.10.1200/JCO.2017.76.7228)| false
BergSL, BlaneySM, DevidasM, et al.. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol2005;23:3376–3382.
BergSL, BlaneySM, DevidasM, . Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 2005;23:3376–3382.10.1200/JCO.2005.03.426)| false
von StackelbergA, LocatelliF, ZugmaierG, et al.. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol2016;34:4381–4389.
von StackelbergA, LocatelliF, ZugmaierG, . Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016;34:4381–4389.10.1200/JCO.2016.67.3301)| false
ToppMS, KuferP, GökbugetN, et al.. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol2011;29:2493–2498.
MaudeSL, LaetschTW, BuechnerJ, . Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378:439–448.10.1056/NEJMoa1709866)| false
MaloneyK, DevidasM, MattanoLA, et al.. Excellent event free (EFS) and overall survival (OS) for children with standard risk acute lymphoblastic leukemia (SR ALL) despite the absence of a significant impact on outcome with the addition of an intensified consolidation: results of Children’s Oncology Group (COG) AALL0331 [abstract]. Blood2013;122:837.
MaloneyK, DevidasM, MattanoLA, . Excellent event free (EFS) and overall survival (OS) for children with standard risk acute lymphoblastic leukemia (SR ALL) despite the absence of a significant impact on outcome with the addition of an intensified consolidation: results of Children’s Oncology Group (COG) AALL0331 [abstract]. Blood 2013;122:837.)| false
AngiolilloA, SchoreRJ, KairallaJA, et al.. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in children with National Cancer Institute (NCI) standard-risk B acute lymphoblastic leukemia (SR B-ALL): a report from Children’s Oncology Group (COG) Study AALL0932 [abstract]. Blood2019;134 (Suppl 1):824.
AngiolilloA, SchoreRJ, KairallaJA, . Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in children with National Cancer Institute (NCI) standard-risk B acute lymphoblastic leukemia (SR B-ALL): a report from Children’s Oncology Group (COG) Study AALL0932 [abstract]. Blood 2019;134 (Suppl 1):824.)| false
AngiolilloA, SchoreR, DevidasM, et al.. Intensification of oral methotrexate is not superior to standard methotrexate dosing during maintenance in children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): a report from Children’s Oncology Group (COG) Study AALL0932 [abstract]. Blood2017;130:140.
AngiolilloA, SchoreR, DevidasM, . Intensification of oral methotrexate is not superior to standard methotrexate dosing during maintenance in children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): a report from Children’s Oncology Group (COG) Study AALL0932 [abstract]. Blood 2017;130:140.)| false
LarsenEC, DevidasM, ChenS, et al.. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group study AALL0232. J Clin Oncol2016;34:2380–2388.
LarsenEC, DevidasM, ChenS, . Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group study AALL0232. J Clin Oncol 2016;34:2380–2388.10.1200/JCO.2015.62.4544)| false
BorowitzMJ, WoodBL, DevidasM, et al.. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood2015;126:964–971.
BorowitzMJ, WoodBL, DevidasM, . Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 2015;126:964–971.2612449710.1182/blood-2015-03-633685)| false
BurkeMJ, SalzerWL, DevidasM, et al.. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica2019;104:986–992.
BurkeMJ, SalzerWL, DevidasM, . Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica 2019;104:986–992.3054592110.3324/haematol.2018.204545)| false
SalzerWL, BurkeMJ, DevidasM, et al.. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group study AALL1131. Cancer2018;124:1150–1159.
SalzerWL, BurkeMJ, DevidasM, . Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group study AALL1131. Cancer 2018;124:1150–1159.2926618910.1002/cncr.31099)| false
TasianSK, AssadA, HunterDS, et al.. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269/AALL1521): dose-finding results from the part 1 safety phase [abstract]. Blood2018;132(Suppl 1):555.
TasianSK, AssadA, HunterDS, . A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269/AALL1521): dose-finding results from the part 1 safety phase [abstract]. Blood 2018;132(Suppl 1):555.10.1182/blood-2018-99-110221)| false
DreierT, LorenczewskiG, BrandlC, et al.. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer2002;100:690–697.
DreierT, LorenczewskiG, BrandlC, . Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690–697.10.1002/ijc.1055712209608)| false
HoffmannP, HofmeisterR, BrischweinK, et al.. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer2005;115:98–104.
HoffmannP, HofmeisterR, BrischweinK, . Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98–104.1568841110.1002/ijc.20908)| false
ToppMS, GökbugetN, ZugmaierG, et al.. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood2012;120:5185–5187.
ToppMS, GökbugetN, ZugmaierG, . Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185–5187.10.1182/blood-2012-07-441030)| false
GökbugetN, DombretH, BonifacioM, et al.. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood2018;131:1522–1531.
KantarjianH, SteinA, GökbugetN, . Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836–847.10.1056/NEJMoa160978328249141)| false
ToppMS, GökbugetN, SteinAS, et al.. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol2015;16:57–66.
ToppMS, GökbugetN, SteinAS, . Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57–66.2552480010.1016/S1470-2045(14)71170-2)| false
ToppMS, GökbugetN, ZugmaierG, et al.. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol2014;32:4134–4140.
ToppMS, GökbugetN, ZugmaierG, . Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134–4140.10.1200/JCO.2014.56.3247)| false
McNeerJL, DevidasM, DaiY, et al.. Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from Children’s Oncology Group. J Clin Oncol2019;37:780–789.
McNeerJL, DevidasM, DaiY, . Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from Children’s Oncology Group. J Clin Oncol 2019;37:780–789.3074255910.1200/JCO.18.00884)| false
MullighanCG, JehaS, PeiD, et al.. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood2015;126:2896–2899.
MullighanCG, JehaS, PeiD, . Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 2015;126:2896–2899.10.1182/blood-2015-09-67113126527677)| false
NachmanJB, HeeremaNA, SatherH, . Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007;110:1112–1115.10.1182/blood-2006-07-03829917473063)| false
PuiCH, ReboraP, SchrappeM, et al.. Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study. J Clin Oncol2019;37:770–779.
KoRH, JiL, BarnetteP, et al.. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol2010;28:648–654.
ParkerC, KrishnanS, HamadehL, et al.. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol2019;6:e204–e216.
ParkerC, KrishnanS, HamadehL, . Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematol 2019;6:e204–e216.10.1016/S2352-3026(19)30003-130826273)| false
SunW, MalvarJ, SpostoR, et al.. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia2018;32:2316–2325.
ParkerC, WatersR, LeightonC, et al.. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet2010;376:2009–2017.
ParkerC, WatersR, LeightonC, . Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010;376:2009–2017.10.1016/S0140-6736(10)62002-821131038)| false
TallenG, RateiR, MannG, et al.. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol2010;28:2339–2347.
TallenG, RateiR, MannG, . Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010;28:2339–2347.2038599610.1200/JCO.2009.25.1983)| false
RaetzEA, BorowitzMJ, DevidasM, et al.. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children’s Oncology Group Study[corrected]. [corrected]J Clin Oncol2008;26:3971–3978.
RaetzEA, BorowitzMJ, DevidasM, . Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children’s Oncology Group Study[corrected]. [corrected]J Clin Oncol 2008;26:3971–3978.10.1200/JCO.2008.16.141418711187)| false
HortonTM, LuX, O'BrienMM, et al.. Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children’s Oncology Group (COG) study (AALL07P1) [abstract]. J Clin Oncol2013;31 (Suppl 15):Abstract 10003.
HortonTM, LuX, O'BrienMM, . Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children’s Oncology Group (COG) study (AALL07P1) [abstract]. J Clin Oncol 2013;31 (Suppl 15):Abstract 10003.)| false
HortonTM, WhitlockJA, LuX, et al.. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol2019;186:274–285.
HortonTM, WhitlockJA, LuX, . Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol 2019;186:274–285.30957229)| false
MessingerY, GaynonP, RaetzE, et al.. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer2010;55:254–259.
MessingerY, GaynonP, RaetzE, . Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer 2010;55:254–259.2058293710.1002/pbc.22456)| false
MessingerYH, GaynonPS, SpostoR, et al.. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood2012;120:285–290.
JehaS, GandhiV, ChanKW, . Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.1455114110.1182/blood-2003-06-2122)| false
JehaS, GaynonPS, RazzoukBI, et al.. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol2006;24:1917–1923.
JehaS, GaynonPS, RazzoukBI, . Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917–1923.10.1200/JCO.2005.03.855416622268)| false
HijiyaN, ThomsonB, IsakoffMS, et al.. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood2011;118:6043–6049.
HijiyaN, ThomsonB, IsakoffMS, . Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043–6049.10.1182/blood-2011-08-37471021967976)| false
MianoM, PistorioA, PuttiMC, et al.. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma2012;53:1693–1698.
MianoM, PistorioA, PuttiMC, . Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma 2012;53:1693–1698.10.3109/10428194.2012.66391522303898)| false
FreyNV, LugerSM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood 2015;126:589–596.10.1182/blood-2014-09-551937)| false
MontilloM, TedeschiA, CenturioniR, et al.. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF). Leuk Lymphoma1997;25:579–583.
SpecchiaG, PastoreD, CarluccioP, et al.. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol2005;84:792–795.
SpecchiaG, PastoreD, CarluccioP, . FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol 2005;84:792–795.1604720310.1007/s00277-005-1090-9)| false
YavuzS, PaydasS, DiselU, et al.. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther2006;13:389–393.
YavuzS, PaydasS, DiselU, . IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther 2006;13:389–393.10.1097/01.mjt.0000181690.21601.0916988532)| false
GabrielMA, O’BrienTA, TappH, et al.. Fludarabine, idarubicin and high dose cytarabine (FLAG-IDA) followed by allogeneic transplantation: a Successful strategy for remission re-induction in high risk pediatric patients with relapsed, refractory and secondary acute leukemias [abstract]. Blood2006;108:3145.
GabrielMA, O’BrienTA, TappH, . Fludarabine, idarubicin and high dose cytarabine (FLAG-IDA) followed by allogeneic transplantation: a Successful strategy for remission re-induction in high risk pediatric patients with relapsed, refractory and secondary acute leukemias [abstract]. Blood 2006;108:3145.10.1182/blood.V108.11.3145.3145)| false
HarrisRE, SatherHN, FeigSA. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children’s Cancer Group experience. Med Pediatr Oncol1998;30:233–239.
HarrisRE, SatherHN, FeigSA. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children’s Cancer Group experience. Med Pediatr Oncol 1998;30:233–239.947375810.1002/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H)| false
ToppMS, GoekbugetN, ZugmaierG, et al.. Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood2011;118:252–252.
ToppMS, GoekbugetN, ZugmaierG, . Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood 2011;118:252–252.10.1182/blood.V118.21.252.252)| false
PortellCA, WenzellCM, AdvaniAS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol2013;5(Suppl 1):5–11.
PortellCA, WenzellCM, AdvaniAS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013;5(Suppl 1):5–11.23671399)| false
GruppSA, KalosM, BarrettD, . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518.10.1056/NEJMoa121513423527958)| false
GruppSA, MaudeSL, RivesS, et al.. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) Acute Lymphoblastic Leukemia. Blood2018;132(Supplement 1):895.
GruppSA, MaudeSL, RivesS, . Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory (r/r) Acute Lymphoblastic Leukemia. Blood 2018;132(Supplement 1):895.10.1182/blood-2018-99-112599)| false
HollymanD, StefanskiJ, PrzybylowskiM, et al.. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother2009;32:169–180.
DavilaML, RiviereI, WangX, et al.. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med2014;6:224ra25.
DavilaML, RiviereI, WangX, . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.10.1126/scitranslmed.3008226)| false
ParkJH, RivièreI, GonenM, . Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018;378:449–459.10.1056/NEJMoa170991929385376)| false
ShahBD, WierdaWG, SchillerGJ, et al.. Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL). J Clin Oncol2017;35(15_suppl):3024–3024.
GruppSA, FreyNV, AplencR, et al.. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Blood2013;122:67.
GruppSA, FreyNV, AplencR, . T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Blood 2013;122:67.10.1182/blood.V122.21.67.67)| false
MaudeSL, FreyN, ShawPA, . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–1517.2531787010.1056/NEJMoa1407222)| false
BrudnoJN, KochenderferJN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321–3330.2720779910.1182/blood-2016-04-703751)| false
KantarjianH, ThomasD, JorgensenJ, et al.. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol2012;13:403–411.
KantarjianHM, DeAngeloDJ, StelljesM, et al.. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med2016;375:740–753.
KantarjianHM, DeAngeloDJ, StelljesM, . Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740–753.2729210410.1056/NEJMoa1509277)| false
DuvalM, KleinJP, HeW, et al.. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol2010;28:3730–3738.
OlianskyDM, CamittaB, GaynonP, et al.. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant2012;18:505–522.
OlianskyDM, CamittaB, GaynonP, . Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant 2012;18:505–522.10.1016/j.bbmt.2011.12.58522209888)| false
HungerSP, SahaV, DevidasM, et al.. CA180-372: An international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood2017;130 (Suppl 1):98.
HungerSP, SahaV, DevidasM, . CA180-372: An international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2017;130 (Suppl 1):98.)| false
JehaS, Coustan-SmithE, PeiD, et al.. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer2014;120:1514–1519.
JehaS, Coustan-SmithE, PeiD, . Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014;120:1514–1519.10.1002/cncr.2859824501014)| false
AricòM, SchrappeM, HungerSP, et al.. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol2010;28:4755–4761.
AricòM, SchrappeM, HungerSP, . Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010;28:4755–4761.2087642610.1200/JCO.2010.30.1325)| false
FieldingAK, RoweJM, RichardsSM, et al.. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood2009;113:4489–4496.
FieldingAK, RoweJM, RichardsSM, . Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009;113:4489–4496.19244158)| false
ChampagneMA, CapdevilleR, KrailoM, et al.. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood2004;104:2655–2660.
ChampagneMA, CapdevilleR, KrailoM, . Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood 2004;104:2655–2660.10.1182/blood-2003-09-303215231574)| false
MartinelliG, BoisselN, ChevallierP, et al.. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol2017;35:1795–1802.
MartinelliG, BoisselN, ChevallierP, . Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017;35:1795–1802.2835511510.1200/JCO.2016.69.3531)| false
AssiR, KantarjianH, ShortNJ, et al.. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk2017;17:897–901.
AssiR, KantarjianH, ShortNJ, . Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 2017;17:897–901.2892778410.1016/j.clml.2017.08.101)| false
GiebelS, CzyzA, OttmannO, et al.. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer2016;122:2941–2951.
GiebelS, CzyzA, OttmannO, . Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 2016;122:2941–2951.27309127)| false
IshidaY, TerasakoK, OshimaK, et al.. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol2010;92:542–546.
IshidaY, TerasakoK, OshimaK, . Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol 2010;92:542–546.2082439910.1007/s12185-010-0678-6)| false
MillotF, CividinM, BrizardF, et al.. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatr Blood Cancer2009;52:891–892.
MillotF, CividinM, BrizardF, . Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Pediatr Blood Cancer 2009;52:891–892.10.1002/pbc.21938)| false
WinterSS, DunsmoreKP, DevidasM, et al.. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer2015;62:1176–1183.
WinterSS, DunsmoreKP, DevidasM, . Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer 2015;62:1176–1183.10.1002/pbc.2547025755211)| false
DeAngeloDJ, YuD, JohnsonJL, et al.. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood2007;109:5136–5142.
DeAngeloDJ, YuD, JohnsonJL, . Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007;109:5136–5142.10.1182/blood-2006-11-056754)| false
WhitlockJ, dalla PozzaL, GoldbergJM, et al.. Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL). Blood2014;124:795.
WhitlockJ, dalla PozzaL, GoldbergJM, . Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL). Blood 2014;124:795.10.1182/blood.V124.21.795.795)| false
HarrisonG, RichardsS, LawsonS, et al.. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol2000;11:999–1006.
HarrisonG, RichardsS, LawsonS, . Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol 2000;11:999–1006.10.1023/A:100838180140311038037)| false
Ramakers-van WoerdenNL, BeverlooHB, VeermanAJ, et al.. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia2004;18:521–529.
Ramakers-van WoerdenNL, BeverlooHB, VeermanAJ, . In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004;18:521–529.10.1038/sj.leu.2403253)| false
